PRNewsWire
29 May 2026, 09:23 UTC · 10h ago
Source · https://www.prnewswire.com/news-releases/menarini-group-presenta-nuevos-datos-del-estudio-elevate-de-elacestrant-en-combinacion-con-capivasertib-302785522.html
Read source
Search tags
Story key points
4 claims · impact-rated
Preliminary data from the ELEVATE phase 1b/2 study shows a median progression-free survival (mPFS) of 11.3 months for the combination of elacestrant and capivasertib in ER+/HER2- metastatic breast cancer. — Strong clinical efficacy data in a difficult-to-treat cancer segment suggests high potential for future regulatory approval and market adoption.
+0.60The combination therapy demonstrated a disease control rate (DCR) of 88.9% and an objective response rate (ORR) of 33.3% in the recommended phase 2 dose (RP2D) cohort. — High control rates provide a factual basis for the drug's potential to become a standard of care for patients with ESR1 and PIK3CA mutations.
+0.50The safety profile of the elacestrant and capivasertib combination was found to be consistent with the known safety profiles of each individual therapy. — A manageable safety profile reduces the risk of clinical trial failure or restrictive black-box warnings during later development stages.
+0.30Continue reading
6 related stories
Menarini Group is evaluating elacestrant in combination with several other agents, including CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors, across multiple trial regimens. — Expanding the pipeline for elacestrant as a backbone therapy increases the long-term valuation of the asset via multiple potential indications.
+0.20Ticker attribution
Model heads
No ticker sentiment head found.
No ticker relationship head found.
Impact vectors
2 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
